Renewable Energy

Pfizer to buy cancer drug developer Array for $10.64 bln

Credit: REUTERS/Arnd Wiegmann

Pfizer Inc said on Monday it would acquire Array Biopharma Inc for $10.64 billion in cash, giving it access to the target's approved drugs for skin cancer and the targeted cancer medicines in its pipeline.

Adds details on deal, background

June 17 (Reuters) - Pfizer Inc PFE.N said on Monday it would acquire Array Biopharma Inc ARRY.O for $10.64 billion in cash, giving it access to the target's approved drugs for skin cancer and the targeted cancer medicines in its pipeline.

The offer of $48 per Array share represents a premium of about 62% to the stock's close on Friday. Array's shares surged 56% in light premarket trade.

Pfizer has been investing in cancer drugs and gene therapies in the face of competition for its blockbuster pain drug Lyrica.

The U.S. Food and Drug Administration last year approved Array's oral combination treatment for use in patients with the deadliest form of skin cancer.

The company is also testing its triple combo therapy in colorectal cancer patients.

"(The acquisition) sets the stage to create a potentially industry-leading franchise for colorectal cancer alongside Pfizer's existing expertise in breast and prostate cancers," Chief Executive Officer Albert Bourla said.

Pfizer said it expects to complete the deal in the second half of 2019.

The transaction is expected to add to earnings beginning 2022, and will be dilutive to adjusted earnings per share by between 4 and 5 cents this year and in 2020, Pfizer said.

(Reporting by Tamara Mathias in Bengaluru; Editing by James Emmanuel and Sriraj Kalluvila)

((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 1208; Reuters Messaging: tamara.mathias.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More